Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision
medicine through quality and innovation; the company’s suite of market-leading molecular profiling offerings
assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make
more precise and personalized treatment decisions.

 

Caris Breast Sample Report
An image Download File 		Sample Report: TNBC – Strong AR Pos – AKT
MI Profile Menu
An image Download File 		The Caris Molecular Intelligence® comprehensive tumor profiling approach to assess DNA, RNA and proteins reveals a molecular blueprint to guide more precise and individualized treatment decisions from among 60+ FDA-approved therapies.
MI GPSai
An image Download File 		MI GPSai™, a Genomic Prevalence Score, uses whole exome (DNA) sequencing and whole transcriptome (RNA) sequencing coupled with machine learning to aid in identifying the tissue of origin.
Genomic LOH
An image Download File 		Caris Life Sciences® utilizes MI Exome™ (whole exome sequencing) to analyze 250,000 evenly-spaced single nucleotide polymorphisms (SNP) to measure genomic instability in the tumor.
MI Reflex Testing Menu
An image Download File 		Comprehensive tumor profiling from Caris Life Sciences® assesses DNA, RNA and Proteins with multiple technologies including Next-Generation Sequencing (Whole Exome Sequencing for DNA), (Whole Transcriptome Sequencing for RNA), PyroSeq, IHC and ISH to reveal a more complete molecular blueprint to guide precise and individualized treatment decisions.
MI Tissue Microdissection
An image Download File 		Did you know that Caris Life Sciences® performs tissue microdissection for every case (where appropriate) to increase the proportion of tumor cells for testing?